
CLAIMS:


1. A compound of formula I




I

wherein

X is




wherein R' is a group (a)




(a)


and either R" is H or OH and R"' is a group (b), (c) or (d)



(b)



(c)



(d)


or R" and R"' each are a group (c),

wherein Z is H, halogen, trifluoromethyl, (C_{1-4})alkyl or (C_{1-4})alkoxy, Q° is -O-, -NH-CO- or a single bond and R° is hydrogen or hydroxy,


Y_1 and Y_2 are H or, when X is  wherein R" is H and R"' is a group (d),

Y_1 and Y_2 can also form together a $-CH_2-CH_2-$ bridge, and

R is a group (e) or (f)



(e)



(f)


wherein

n is 0 to 3

R_1 is H, (C_{1-4})alkyl or $-SO_2-CH_3$

R_2 is H, halogen, (C_{1-4})alkyl, (C_{1-4})alkoxy, (C_{1-4})alkylthio or phenyl,

R_3 is H, (C_{1-4})alkyl or a group (g)



(g)

wherein Z is as defined above,

R_4 and R_5 each are H or together form a bond, or R_4 is H and R_5 is (C_{1-4})alkoxy,

R_6 is (C_{1-4}) alkyl or a group (g) and

R_7 is (C_{1-4}) alkoxy,

provided that when X is $>N-R'$, R is of formula (f) and n is 0, then Z is different from fluor in free base or acid addition salt form.


2. [3S, 4aR, 10aR]-3-(endo-3-Benzhydryloxy-8-aza-bicyclo[3.2.1]oct-8-ylmethyl)-6-methoxy-1-methyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline in free base or acid addition salt form.

3. [3R, 4aR, 10aR]-3-(endo-3-Benzhydryloxy-8-aza-bicyclo[3.2.1]oct-8-ylmethyl)-6-methoxy-1-methyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline in free base or acid addition salt form.

4. [6aR, 9R]-9-[2-(endo-3-Benzhydryloxy-8-aza-bicyclo[3.2.1]oct-8-yl)-ethyl]-7-methyl-4,6,6a,7,8,9-hexahydro-indolo[4,3-fg]quinoline in free base or acid addition salt form.

5. A process for the preparation of a compound of formula I as defined in claim 1, or a salt thereof, which includes the step of


a) reducing a compound of formula II



II

wherein X, Y_1, Y_2 and R are as defined in claim 1, or

b) reacting a compound of formula III



III

wherein X, Y_1 and Y_2 are as defined in claim 1, with a compound of formula IV

$$R\text{-}CH_2\text{-}Q \qquad IV$$


wherein R is as defined in claim 1 and Q is halogen, mesyl or tosyl,

and recovering the thus obtained compound of formula I in free base or acid addition salt form.

6. A compound of any one of claims 1 to 4 in free base or pharmaceutically acceptable acid addition salt form, for use as a pharmaceutical.

7. A compound of any one of claims 1 to 4 in free base or pharmaceutically acceptable acid addition salt form, for use in the treatment of any state resulting from Aβ accumulation or deposition in brain tissue.

8. A pharmaceutical composition comprising a compound of any one of claims 1 to 4 in free base or pharmaceutically acceptable acid addition salt form, in association with a pharmaceutical carrier or diluent.



9. The use of a compound of any one of claims 1 to 4 in free base or pharmaceutically acceptable acid addition salt form, for the manufacture of a medicament for the treatment of any state resulting from Aβ accumulation or deposition in brain tissue.